-
公开(公告)号：US12235278B2
公开(公告)日：2025-02-25
申请号：US17270830
申请日：2019-08-23
Applicant: Beth Israel Deaconess Medical Center, Inc.
Inventor： Robert Flaumenhaft , David Barrios , Secil Koseoglu
Abstract: In some aspects, the disclosure relates to compositions and methods for detecting phosphorylation of dynamin-related protein 1 (Dip1) at position Ser-616. In some embodiments, methods described by the disclosure are useful for detecting antiplatelet agent sensitivity in a subject. In some embodiments, methods described by the disclosure are useful for detecting if a subject has been previously exposed to an antiplatelet agent.
-
公开(公告)号：US20180370912A1
公开(公告)日：2018-12-27
申请号：US15637597
申请日：2017-06-29
Inventor： Robert Flaumenhaft , Partha Pratim Nag
IPC: C07D209/08 , A61K31/4045
Abstract: Provided herein are compounds of Formula I: and pharmaceutically acceptable salts and compositions thereof for use in treating diseases associated with the activity or expression of protein disulfide isomerase, wherein the variables are as described herein.
-
3.发明申请COMPOUNDS AND COMPOUNDS FOR USE IN METHODS FOR TREATING DISEASES OR CONDITIONS MEDIATED BY PROTEIN DISULFIDE ISOMERASE 审中-公开用于治疗由蛋白质分解异构体介导的疾病或病症的方法中的化合物和化合物公开(公告)号：US20160145209A1
公开(公告)日：2016-05-26
申请号：US14899180
申请日：2014-06-20
Inventor： Robert Flaumenhaft , Partha Pratim Nag , Tatiana Pilyugina , Jun Pu , Sivaraman Dandapani , Benito Munoz
IPC: C07D211/62
CPC classification number: A61K31/445 , A61K31/454 , C07D211/62 , Y02A50/385 , Y02A50/409
Abstract: The invention provides compounds of formula (I) that inhibit PDI, for use in methods to treat or prevent a disease or condition in a subject that would benefit by inhibition of PDI. Formula (I)
Abstract translation: 本发明提供抑制PDI的式（I）化合物，用于治疗或预防受试者受益于PDI抑制的疾病或病症的方法中。 式（I）
-
4.发明公开公开(公告)号：US20240133897A1
公开(公告)日：2024-04-25
申请号：US17783180
申请日：2020-12-09
Applicant: Beth Israel Deaconess Medical Center, Inc.
Inventor： Jeffrey I. Zwicker , Robert Flaumenhaft
IPC: G01N33/68
CPC classification number: G01N33/6893 , G01N2333/4706 , G01N2333/99 , G01N2800/226 , G01N2800/50 , G01N2800/52
Abstract: The present invention relates to compositions and methods for identifying at-risk patients and modulating thrombotic conditions in a cancer patient. Embodiments provided herein include a method of determining risk for a thrombotic event in a cancer patient comprising: detecting in a sample of a patient with cancer elevated levels of PPIA, PDIA3 and at least one of EIF5A, EIF4H, EIF4a3, UBE2N, UBE2L3, UBE2I, and HSP70.
-
Patent Agency Ranking
公开(公告)号：US20240016777A1
公开(公告)日：2024-01-18
申请号：US18252502
申请日：2021-11-12
Applicant: Beth Israel Deaconess Medical Center, Inc.
Inventor： Robert Flaumenhaft , Lin Lin
IPC: A61K31/353 , A61K9/00 , A61K31/7048 , A61K45/06 , A61P31/14 , A61P7/02
CPC classification number: A61K31/353 , A61K9/0043 , A61K31/7048 , A61K45/06 , A61P31/14 , A61P7/02
Abstract: The present application provides a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions containing the compound of Formula (I), and methods of using the compound of Formula (I) for treating viral infections and inhibiting thromobosis are also provided.
-
6.发明申请公开(公告)号：US20170304283A1
公开(公告)日：2017-10-26
申请号：US15632809
申请日：2017-06-26
Inventor： Robert Flaumenhaft , Partha Pratim Nag , Tatiana Pilyugina , Jun Pu , Sivaraman Dandapani , Benito Munoz , Chris Dockendorff
IPC: A61K31/445 , A61K31/454
CPC classification number: A61K31/445 , A61K31/454 , C07D211/62
Abstract: The invention provides compounds of formula (I) that inhibit PDI, for use in methods to treat or prevent a disease or condition in a subject that would benefit by inhibition of PDI. Formula (I).
-
公开(公告)号：US11872241B2
公开(公告)日：2024-01-16
申请号：US16696280
申请日：2019-11-26
Applicant: Beth Israel Deaconess Medical Center, Inc.
Inventor： Jeffrey I. Zwicker , Bruce Furie , Jack Davis Stopa , Robert Flaumenhaft
IPC: A61K31/7048 , A61K31/352 , A61P35/04 , A61K31/375 , A61K31/519 , A61K31/45
CPC classification number: A61K31/7048 , A61K31/352 , A61K31/375 , A61K31/45 , A61K31/519 , A61P35/04
Abstract: The present invention relates to methods for reducing soluble P-selectin and major thrombotic events in cancer patients.
-
公开(公告)号：US20210181214A1
公开(公告)日：2021-06-17
申请号：US17270830
申请日：2019-08-23
Applicant: Beth Israel Deaconess Medical Center, Inc.
Inventor： Robert Flaumenhaft , David Barrios , Secil Koseoglu
Abstract: In some aspects, the disclosure relates to compositions and methods for detecting phosphorylation of dynamin-related protein 1 (Dip1) at position Ser-616. In some embodiments, methods described by the disclosure are useful for detecting antiplatelet agent sensitivity in a subject. In some embodiments, methods described by the disclosure are useful for detecting if a subject has been previously exposed to an antiplatelet agent.
-
公开(公告)号：US10064853B2
公开(公告)日：2018-09-04
申请号：US15632809
申请日：2017-06-26
Inventor： Robert Flaumenhaft , Partha Pratim Nag , Tatiana Pilyugina , Jun Pu , Sivaraman Dandapani , Benito Munoz , Chris Dockendorff
IPC: A61K31/445 , A61K31/454
Abstract: The invention provides compounds of formula (I) that inhibit PDI, for use in methods to treat or prevent a disease or condition in a subject that would benefit by inhibition of PDI. Formula (I)
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.067 seconds)
